Epigenetic induction of adaptive immune response in multiple myeloma: sequential azacitidine and lenalidomide generate cancer testis antigen‐specific cellular immunity

Abstract excerpt

Patients with multiple myeloma (MM) undergoing high dose therapy and autologous stem cell transplantation (SCT) remain at risk for disease progression. Induction of the expression of highly immunogenic cancer testis antigens (CTA) in malignant plasma cells in MM patients may trigger a protective immune response following SCT. We initiated a phase II clinical trial of the DNA hypomethylating agent, azacitidine...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Histone Deacetylase Inhibitors Research
• Share to Immunotherapy and Immune Responses
• Share to Multiple Myeloma Research and Treatments